tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate

Application of tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate (CAS: 571188-59-5)

I. Core Pharmaceutical Applications (Primary Use)

1. Key Intermediate for Palbociclib
   • It is a core building block for CDK4/6 inhibitors (Cyclin-Dependent Kinase 4/6 inhibitors), such as Palbociclib (a targeted therapy for breast cancer). It provides the pyridine-piperazine core structure fragment and is essential for the industrial production of this API.
   • The Boc (tert-butoxycarbonyl) protecting group can be gently removed in later synthesis steps, ensuring selectivity in subsequent coupling and cyclization reactions, reducing impurities, and guaranteeing API purity and efficacy.
    
2. Intermediate for Other CDK4/6 Inhibitors
   • It can be used for structural modification and synthesis of other CDK4/6 inhibitors, including Ribociclib and Abemaciclib, adapting to the molecular framework construction of similar kinase inhibitors.
    
3. R&D of Kinase Inhibitor Drugs
   • With its pyridine-piperazine heterocyclic structure, it acts as a general synthetic building block for other kinase inhibitors (e.g., JAK, FLT3, EGFR), used in laboratory R&D and process optimization for antitumor, anti-inflammatory, and immunomodulatory drugs.
    

II. General Organic Synthesis Applications

1. Building Block for Nitrogen-Containing Heterocyclic Compounds
   • The molecule contains three reactive sites: 6-aminopyridine, piperazine, and Boc protecting group. It can construct various nitrogen-containing heterocyclic drug molecules through deprotection, nucleophilic substitution, condensation, and cyclization, supporting the structural diversification of small-molecule drugs.
    
2. Structural Modification of Drug Molecules
   • As a linker/side-chain fragment, it is introduced into drug molecules to enhance target binding affinity, water solubility, or metabolic stability, widely used in structural optimization of antitumor, anti-infective, and neurological drugs.
    

III. Application Characteristics and Positioning

• It is a high-purity pharmaceutical intermediate, mainly supplied to API manufacturers and CRO/CDMO companies. It is not used directly as a formulation or API, but requires multi-step synthesis to be converted into final drugs.
• Its core value lies in providing the key structural unit for CDK4/6 inhibitors, supporting the industrial production and R&D of targeted therapies for malignant tumors such as breast cancer.

Contact information:

Contact: Sophia Li

Email: sophia@coreychem.com